148 related articles for article (PubMed ID: 37048107)
1. An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration.
Virdi AK; Ho S; Seaton MS; Olali AZ; Narasipura SD; Barbian HJ; Olivares LJ; Gonzalez H; Winchester LC; Podany AT; Ross RD; Al-Harthi L; Wallace J
Cells; 2023 Mar; 12(7):. PubMed ID: 37048107
[TBL] [Abstract][Full Text] [Related]
2. Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice.
Dyavar SR; Gautam N; Podany AT; Winchester LC; Weinhold JA; Mykris TM; Campbell KM; Alnouti Y; Fletcher CV
J Antimicrob Chemother; 2019 Oct; 74(10):2974-2978. PubMed ID: 31335938
[TBL] [Abstract][Full Text] [Related]
3. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
5. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
6. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
7. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
[TBL] [Abstract][Full Text] [Related]
8. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
9. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Tenorio AR; Pappa KA; Wynne B; Gartland M; Aboud M; van Wyk J; Smith KY
J Acquir Immune Defic Syndr; 2020 Mar; 83(3):310-318. PubMed ID: 31834000
[TBL] [Abstract][Full Text] [Related]
10. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
[TBL] [Abstract][Full Text] [Related]
11. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies.
Ait-Khaled M; Sierra Madero J; Estrada V; Gulminetti R; Hagins D; Tsai HC; Man C; Sievers J; Grove R; Zolopa A; Wynne B; van Wyk J
HIV Res Clin Pract; 2021 Dec; 23(1):9-14. PubMed ID: 34913844
[No Abstract] [Full Text] [Related]
12. Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice.
Weichseldorfer M; Affram Y; Heredia A; Rikhtegaran-Tehrani Z; Sajadi MM; Williams SP; Tagaya Y; Benedetti F; Ramadhani HO; Denaro F; Munawwar A; Bryant J; Zella D; Reitz M; Romerio F; Latinovic OS
J Transl Med; 2021 Oct; 19(1):453. PubMed ID: 34717655
[TBL] [Abstract][Full Text] [Related]
13. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
17. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
18. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
19. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA
J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
